Glenmark Pharma Receives Final Approval By MHRA For Maloff Protect

Glenmark Pharmaceuticals Europe (Glenmark) has been granted final approval by the MHRA (Medicines and Healthcare products Regulatory Agency) for Maloff Protect (250mg/100mg atovaquone/proguanil film-coated tablets), anti-malarial medication, as a pharmacy license in the United Kingdom.

Maloff Protect will be used in the prevention of malaria in adults travelling to areas where malaria is prevalent.

Maloff Protect contains atovaquone and proguanil hydrochloride, and has been available only as a prescription medicine in the UK. Under this approval, patients will be able to purchase Maloff Protect without a prescription.

Meanwhile, the stock on Tuesday’s trade gained 0.76% at Rs 644.20 per share.

BSE Healthcare index gained over 39 points or 0.28% at 14266.63 level. Nifty pharma index gained 20 points or 0.67% at 3066.60 level on Tuesday’s intraday trade.

For Quick Trial – 8962000225 ✔
or mail us here:
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717 
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.